# Health Care Originals AI-powered care giving people their lives back. Validated. Contracted Distribution. Scaling fast. - Canonical URL: https://wefunder.com/hco - Entity ID: wefunder:company:67542 - Last updated: 2026-06-14T23:53:33Z - Generated at: 2026-06-15T04:14:24Z ## Quick facts - On track for $1M MRR by Q1 2027. This round gets us to cash-flow positive. - Backed by leading venture funds Safar Partners, Chloe Capital, Kingscrowd Capital, D3VC.ai - We are defining a new category: Physical AI for chronic conditions. 26 patents allowed & ending. - One platform. Every organ. Respiratory and Neuro deployed; Cardiology, Speech AI and GI are next. ## Active fundraises - wefunder:fundraise:118615: 4(a)(6) successful (USD) - wefunder:fundraise:118614: 4(a)(6) successful (USD) ## Investor memos - Safar Partners: https://uploads.wefunder.com/uploads/remote_files/886605-vzmOW88rzMhniAcTfLN94Y3X/HCO_Safar_Partners_Investment_Memo_.pdf ## Story We are privately inviting existing investors and new friends to invest first, with preferred terms. This is only available to accredited investors.If you'd like to explore an investment of $5,000 or more, I'm happy to schedule a call with you. Please reach out to me directly at sharon.samjitsingh@healthcareoriginals.com.If you are not accredited, or would like to invest less than $5,000, we are planning to open up a Community Round in August for everyone to participate in our future growth, and we look forward to welcoming you.Thank you!We Make the Invisible ActionableOur bodies are constantly communicating. Every breath, every movement, every recovery attempt leaves signals behind. Those signals are often present weeks before a crisis. Healthcare simply has not had a practical way to listen.We are driven by a simple idea: the future of healthcare belongs to systems that continuously understand how people are breathing, moving, and recovering. Not during an annual checkup. Every day.We started in respiratory disease because the need was urgent and personal. Our CEO Sharon Samjitsingh has lived with asthma her entire life, done everything right, and still nearly died five times. That experience drives every product decision we make.Respiratory affects more than 600 million people worldwide. But respiratory was never the category. Physical AI in chronic disease management is. Long before that term entered the mainstream conversation, we were already building it.We're now growing and demonstrating the proof. Our acquisition of Imago Rehab expanded the platform into stroke recovery, neurorehabilitation, and speech therapy. Different conditions, but the same fundamental challenge: getting people the right support at the right moment, before a crisis occurs.HCO owns the entire feedback loop. We capture the signals. We build the intelligence that interprets them. We deliver the care that responds. Every interaction makes the platform smarter. Each new disease category we enter costs a fraction of the last.We call it making the invisible actionable. It's one of the largest uncaptured opportunities in healthcare, and we are already capturing it.LTV: Lifetime Value; CAC: Cost of Customer Acquisition; NPS: Net Promoter ScoreThe graphic above tells part of the story. Here is the rest.In Respiratory, we have signed contracts covering 400,000 lives. We were exclusively chosen by the Asthma and Allergy Foundation of America for their HEAL program. Two additional health plans are in active evaluation representing $129M in avoidable spend.In Neuro, we acquired Imago Rehab and turned it around completely. In five months: 3X revenue growth, 76% CAC reduction, first positive contribution margin in the business's five-year history. NPS is 95. We are waitlisted in most states.We are no longer asking whether this approach can work. We are focused on how far it can go.One Platform. 3 Layers.For generations, physicians were trained to learn from the body itself. They listened to heart sounds, lung sounds, pulse points, and vibrations. Those signals often provided the earliest clues that something was changing. The problem was never that the signals lacked value. The problem was scale.A physician can only listen occasionally. A patient lives with their condition every day.Our co-founder Jared, named on all our patents, has often said he wants our technology to become as ubiquitous as the household thermometer. Not because it diagnoses disease on its own, but because it transforms something previously subjective into something measurable and actionable. A thermometer became indispensable for exactly that reason. We believe the same opportunity exists across a much broader range of physiological signals.Respiratory was the first application. The platform has always been the objective.SignalsOur proprietary technologies capture physiological signals that are often invisible to patients, clinicians, and traditional monitoring systems. ADAMM continuously listens to the lungs and airways. In neurorehabilitation, our soft robotic systems capture movement, effort, and recovery progress in the home. These signals create a continuous picture of what is actually happening inside the body, rather than relying on occasional clinic visits or patient recollection.IntelligenceThose signals feed Aidah, our AI intelligence layer. Aidah is built on the idea that every individual has a unique physiological baseline, and that meaningful deterioration often appears first as subtle changes rather than dramatic events. Aidah continuously builds a living model of each person, identifying patterns, predicting risk, and determining which interventions are most likely to help.CareInsight must become action. The final layer is care itself, delivered through respiratory therapists, occupational therapists, physical therapists, and speech therapists, and increasingly through AI-powered support that extends their reach. Every interaction generates new information, strengthening the underlying model and improving future care.Respiratory proved the model. Neuro proved it transfers. The platform is what scales.Large language models like Claude and ChatGPT have demonstrated extraordinary capabilities and will play an important role in healthcare. But they are fundamentally trained on text. They learn from what has already been written, documented, and observed.Many healthcare AI companies are built on that same foundation. They rely on data generated by someone else's devices, someone else's care models, or someone else's patients.Meet Aidah.Aidah is different because it is trained on what people do.At the center of Aidah is what we call the Living Patient Model: a continuously evolving understanding of an individual built from physiological signals, clinical context, behavioral patterns, interventions, and outcomes. Rather than relying on population averages, Aidah learns what is normal for a specific person, recognizes when something changes, and helps determine which interventions are most likely to help.This is what makes Aidah a Physical AI platform. Its intelligence is grounded in the real world. Every signal adds context. Every intervention provides feedback. Every outcome improves understanding.Most importantly, we own the entire loop.We build the sensing technologies that capture the signals. We deliver the therapist-guided care that generates interventions. We own the outcomes data that closes the loop. Aidah sits at the center, learning from all three. That creates an advantage that compounds with every new member and every new disease category we enter.Respiratory was our first application. Neuro was our second. Aidah is the intelligence layer that allows the platform to expand far beyond either one.With 26 patents issued and pending, combined with a data advantage, we've built a moat that compounds exponentially.In HCO Respiratory, we sell to payers, who bring us their population of people who need help avoiding ER visits and hospitalizations. Our current contracts are structured as a per-engaged-member-per-month fee with quality bonuses, and we are now moving to value-based contracts as they generate more revenue. We are now in evaluation for opportunities that could generate $25M in revenue. In Neuro, we operate fee-for-service.HCO Neuro is on track to reach $500K monthly recurring revenue by Q4 2026, bringing the combined entity to cash-flow positive by Q2 2027. Every payer contract that closes between now and then is upside on top of that.This is not a company that exits once. HCO's model is to incubate each disease vertical to a monetized ARR threshold, then spin it off as an independent company. HCO retains 100% equity at inception. Each entity raises its own capital. Investors in this round own a stake in all four verticals: Respiratory, Neuro, ReSpeak AI, and Cardiology, with exit comparables ranging from $0.6B to $4B in adjacent categories. HCO enters each one with stronger clinical proof and more contracted distribution than any comparable company had at equivalent stage.Safar Partners is leading this round, as they have led every round of capital HCO has raised since they first invested. Cranberry Capital, our first institutional investor, has maintained their pro rata. When your earliest investors keep writing checks, it means something.This round gets HCO to cash-flow positive. Not on the strength of projections alone, but because HCO Neuro reaches $500K MRR by Q4 2026 on current trajectory, and that single milestone brings the combined entity there. The downside is cash-flow positivity. Everything else in the pipeline is upside.The terms are straightforward. This is a SAFE note at a $45M pre-money cap with a 20% discount to the next priced round. $1.5M is committed. $3M remains.If you invested in our Reg CF campaign, thank you. You helped us build what you are looking at now. This is your chance to go further, on the same terms as our lead VC.If you are new to HCO, the hardest part is done. What remains is scale.Reach out directly: sharon.samjitsingh@healthcareoriginals.com ## FAQ 1. **Hello Sharon, This is an awesome initiative. I can appreciate how valuable this project for the people that suffer from Asthma. Growing up, it was hard to see my Dad quickly drift in emergency especially overnight time and again. I am glad you and your team are going after a p...** - Dear Prakash, Thank you for your kind words, for sharing your story about your Dad, and for your investment! I understand completely - my attacks always seemed to be worse at night, and at Christmas time, and it made for some scary experiences. I can't agree with you more about Wefunder and this ONE great community. Also, not for nothing, I'm a great fan of a well-placed ellipsis like yours ... I appreciate your interest in a call as well. I sent you an email with some times for us to connect... 2. **As a respiratory therapist and a physician assistant, I'm always looking to seek out and support devices/companies that make a big impact on the patients I care for. This seems like a really innovative product. How does what the device hears/senses, does that correlate with me...** - Dear Adam, First, I just have to say it - did you know our device was first called ADAM when it was conceived in the mind of a brilliant researcher at the University of Rochester? We added an extra M, so now it's called ADAMM, but I just had to point that out. As you can see from our model, we value Respiratory Therapists significantly - so thank you for the work you do both as an RT and a PA. We are thrilled to lead a company where Respiratory Therapists can fulfil their calling around self-... 3. **If I invest now do I get the Early Bird Bonus? I see EARLY BIRD TERMS: $130,045 LEFT** - Hello Grigore! Yes, absolutely, if you invest now you still get the early bird terms. 4. **Hello Sharon, Really appreciate the direction you're taking with ADAMM. Could you provide more detail on how the AI is utilized within the platform? Specifically, does the AI learn from individual patient data—or even across all patients—to continually improve the guidance and...** - Great question Maxime! And thank you for your kind words. For clarity going forward, we use the word members interchangeably with patients. We use AI in a couple ways and are going to expand our uses with this fund raise. As long as our members consent, we use the data to continually improve what we call our actionable insights. This could be data from one member used in their own feedback loop, or data across members to train recognition of various sounds. We utilize multiple sensors in the ... 5. **Hi Sharon, I’m Zac with D3VC. We specialize in investment crowdfunding and are intrigued by your offering, especially given your team's expertise. I’d love to learn more about your experience with AI—how do you plan to incorporate it into your product development? Specifically...** - Zac, thanks for the insightful questions, and have to say I appreciate D3VC's data-driven approach to identifying who to diligence for investment. It's very akin to our approach - eliminating bias that tends to be inherent in so many of the standard measures that are used in respiratory testing and diagnosis today. We like to say that the sound of our deep organs doesn't depend on race, ethnicity or zip code, and therefore we have unparalleled, non-invasive objective insights to inform mass p... ## Team - Sharon Samjitsingh (CEO & Co-Founder) - Jared Dwarika (COO & Co-Founder) - Jennifer Chambers (Chief Medical Officer, MD MBA FACP) - Cameron Jacox (Chief Growth Officer) - Doug Roy (SVP, Business Development) - Kristin Nuckols (Chief Clinical Officer, Imago Rehab) ## Recent posts - April Investor Update! (2026-05-18T22:00:00Z) - March 2026 Update (2026-04-20T23:00:00Z) - HCO Investor Update – February 2026 (2026-03-10T22:17:11Z) - HCO Investor Update – January 2026 (2026-02-16T20:36:02Z) - 2025: A Year of Growth, Gratitude, and Groundwork (2026-01-14T21:49:49Z) - HCO Investor Update – November 2025 (2025-12-07T18:33:34Z) - We Did It – $1.1M Raised. Thank You. 💙 (2025-09-30T14:10:04Z) - 🚨LAST CALL & Thank you 🚨 (2025-09-29T00:00:22Z) - 🚨Final Hours to Invest (2025-09-28T18:51:23Z) - ⌛Last Chance to Invest: Community Round Closes TODAY! (2025-09-28T14:00:34Z) - 🎉$1M Raised. 500 Investors. New Project. Closing Tomorrow! (2025-09-27T18:00:09Z) - ⏰48 HOURS left + $1M Additional Contracted Revenue Approved! (2025-09-26T16:13:32Z) - Watch Our Final Investor Webinar + Vote on Our New Look 👀 (2025-09-25T14:33:13Z) - Kingscrowd Analyzes the Imago Acquisition + HCO is a Most Searched Startup! 👑 (2025-09-24T15:53:56Z) - National Spotlight with the Asthma & Allergy Foundation of America 🏆 (2025-09-23T15:00:13Z) ## Q&A - Q: I see there were these notes: $1,250,000 Issued 3/1/24 18% Maturity 2/27/27. Is this convertible to stock and if so, at what valuation? $8,539,314 Issues 5/1/24 Maturaty 12/31/24. It shows a 19% interest Convertible note at a $15,000,000 valuation, with a 20% discount. Was this converted, and if so, when and at what valuation? If it was not converted how will it be paid and how will the $1,250,000 loan be paid? Will it be paid from revenue since it does not show any of the money being raised is to pay off loans. I hope to have additional funds to invest in the next 6 weeks, and I am strongly considering increasing our investment if funds are still needed. - A: Hi Alan, Thanks for your continued interest! The $1.25M loan is not convertible to stock. It's a simple interest loan, which will be repaid from revenue in one payment in 2027 when it is due. The convertible note was already converted - conversion was automatically triggered by this equity round. All of these notes were converted to equity, so there's no repayment due for those. We appreciate your thorough due diligence and willingness to invest more! We can't guarantee how long the round will be open for, but if it's still open, we welcome your investment. - Q: Hi I just joined the platform and was considering investing between $5,000 and $50,000 because of the 1.5X bonus. But I am not sure if I will qualify. I see it applies only to the first $400,000. Please clarify. thanks, Alan - A: Alan, thanks for your interest and welcome to community investing on Wefunder! Thrilled to be in consideration for an investment. The 1.5X warrants applied to everyone in the first $400,000 as an early bird bonus but are STILL applied to Wefunder VIP Investors. Therefore, if you're a VIP member, then you would still qualify for the 1.5X bonus. - Q: This may be a dumb question but for the 12k people on the waitlist, what are they waiting for? Insurance approval? Or do you need to create more of the product to ship? Or something else ? Thanks in advance - A: Kenneth, thank you for your interest, and absolutely no question is ever a dumb question in our eyes. There are already existing insurance reimbursement codes for which our services qualify, so we've already done all of the work to identify and ensure we can bill those processes. That's only one step of the process though - we have to then roll out state by state and then get approved to bill these codes by each insurance in each state. So we're systematically rolling out, which is why we mentioned in our latest update that we had expanded to 3 states, 23 insurances. This takes time and capital to scale as you can imagine, and is one of the use of funds from this round. This fundraising round is all about scaling - our offerings work, so now it's about growing revenue meaningfully while still ensuring we make margin. You'll find us to be the "measure twice, cut once" team - we progress in a manner that ensures we keep a clear eye on the fundamentals that matter - like margin. We've learned from these existing contracts though, and our aim for the new contracts in our pipeline is to sign with the entities that will allow us to perform these steps quicker and faster. - Q: Hi. Are the 13 patents allowed with 10 more pending mentioned in the overview owned by HCO or by yourself and Jared? Also, please explain the means by which the device adheres to the skin. Thank you. - A: Hi Stephen, appreciate your interest! I'm happy to say HCO now has 14 patents allowed, with 9 pending. While my Co-Founder Jared and I are named as inventors on patents, all HCO-based patents on which we are named inventors have been assigned to HCO, so HCO is the owner. In addition to these, there is one patent that we have licensed from the University of Rochester. HCO holds an exclusive license for this patent for all fields of use for the life of the patent. All employees of HCO, including the Co-Founders, sign IP agreements at the time of employment, assuring that any IP developed during employment is owned by HCO. To avoid confusion, I am also a named inventor on other patents in the field of renewable energy and materials as a result of my work in the sustainability field. Those patents have been rightfully assigned to the organization with which I worked at that time. The device adheres to the skin using an adhesive that is specially cut to fit the shape of the device. We use 3rd party adhesives that are wound-closure-grade, meant to be stuck to the body for long periods of time, and which have gone through full cytotoxicity and other testing, with relevant filings made at the FDA. - Q: This techology is very helpful for monitoring serious asthma and COPD. Can this technology also be used for Diabetes by measuring blood glucose, A1c, and/or C-peptide levels? Wearable technology to detect blood glucose is already available. I feel this company could corner the market - A: Hi Rebecca, great question. I always talk about our vision for our device as being "the one device to rule them all", somewhat jokingly but also true because that was our intent when we designed it. It's a very powerful body hub that can process inputs from many, many sensors, beyond even acoustics. And we've only just begun. There's lot we can do and sense without being invasive. Happy to talk some more about that if you're interested. - Q: Your answer is very satisfactory 😀even if everyone got 1.5x shares and there is a post raise valuation of 17/18 million hco is worth a lot more! - Q: Just to understand this whole concept with bonus shares and warrants are you just printing more shares which doesn’t help us investors out by having a larger number of shares or are we getting more shares from the original supply? Meaning owning 10 shares out of 100 shares and 100 shares out of 1000 shares is the same. What’s will be the final amount of shares after all warrants are excersized and what will be the valuation based on that number of shares - A: Hi Eliezer, every time an equity round is done, it means the company is selling more shares than it did in its last equity round. If we didn't do that then it would mean that there would be no shares for the company to sell. So, just like every equity round in every investment, we will have more shares outstanding at the end of this round than at the beginning of this round. The 1.5X warrants absolutely present an advantage to the investor. In a typical round where $3M is raised on a $13M pre-money, the post-money valuation would be $16M. As an example, someone investing $10,000 in a round like that would own 0.06% of the company at the end of the round. In this round, that same investment, because of the warrants, gets you 0.077% of the company at the end of the round. - Q: Sharon, Sorry, I meant to say that I am *now* a VIP member of Wefunder, not "not." Thanks, James - A: James, my apologies - I thought I had replied to you on Saturday, but I must have forgotten to hit "Post". I'm normally much more responsive. Confirming that you will automatically get the 1.5X warrants on any investments you make after becoming a VIP. Thanks for being an investor! - Q: Sharon,The investments I made in HCO so far were before I became a Wefunder VIP, but I am not a Wefunder VIP. How can I get the 150% bonus shares with the warrants now? Do I need to increase my investment? What is the process?Thanks, James - A: Thanks James, please see answers above. - Q: Are the vip terms still available I want to invest 2 k. and what would be the difference if I am vip or not? Meaning how many shares will I get as vip and how many if I’m not - A: Eliezer, thank you for your interest in investing! Yes, VIP terms are still available. The difference is ~1,268 shares - Q: Is this FDA approved? How extensively is it being used throughout the United States and do you have pulmonologist who share information about this surveillance modality with their patients? - A: Dr. Stewart, thank you for your investment and interest! Thank you for your years of dedication to access and equity. This has been extensively used in the US and in Canada in our clinical studies market segment. In our segment with the most traction - our service where we on the basis of improved outcomes and reduced cost of care to members, payers, self-insured employers, MCOs, ACO Reach organizations, etc., we have been used in approximately 20 states. Our current claims do not require us to have FDA 510K clearance, and we stay within the limit of what we can claim in our marketing materials. We don't market to pulmonologists but have a few on board who are aware and help us. Happy to answer any further questions you may have. Look out for an email from me - I send each investor a personal thank you email so they all have my contact information. - Q: Dear, I hope this message finds you well. I came across your business listing and I’m very interested in learning more about the opportunity. I would appreciate the chance to discuss further details with you. Would you be available for a quick call or Zoom meeting? You can reach me directly at +41 766 501 494, or feel free to book a time that suits you via my Calendly link: https://calendly.com/adam-zhusupov/30min Looking forward to speaking with you soon. Best regards, Adam Zhusupov - A: Thank you Adam. I booked some time for us to speak. - Q: Hi sharon, with this round soon to close and a new one is planed... is there a plan for warrants or other options for us who participated in this round to reduce dilution ? Thanks - A: Ali, thanks as always for the thoughtful question. All investors in this round get warrants already. Everyone agrees that the terms of this round are really not reflective of where HCO is today, and the valuation is too low. So, with the normal caveat that future projections and proformas are not guaranteed, our plan is that future rounds will be priced at a significant step-up in valuation that reflects more accurately where the company will be at that time. In short, the time to get in (and I know you have already) is now, because there's never going to be better value for an investor. - Q: Is the VIP bonus of 1.5x warrants still being offered, or has that passed? - A: Marco, thanks for your interest! Yes, the VIP bonus is still being offered. As of this writing, we have about $35K left in the allocation. - Q: Hello. I am loving all of your progress, and you all are doing great! Just a clarification about warrants, when will we see those in our account? With my prior investments, it shows the shares based off that price, without warrants. - A: Thank you Adam! It means a lot for us to hear this from our community! And thanks for asking the question as a few others have been asking via email. As a reminder, we're the first company to offer warrants on Wefunder. The warrants automatically convert into shares at the time your investment is confirmed, however the Wefunder team has flagged that their automated processing doesn't necessarily show the conversion automatically because it's so unique. So, we're doing an exercise with them where we're working through the investments one by one and agreeing to each so they can update accounts. We started, and we're hoping to have it completed within a couple weeks of the round closing. Thanks for your patience! We'll generate an investor-only update soon to clarify this as well, just in case people miss this question.